On October 6, Vaxcyte, Inc. fell 5.92% in regular trading, trading at $67.455, with Turnover of $24.7741 million. The decline came after the company announced a public offering of common stock, pre-funded warrants, and convertible senior notes, triggering market concerns over equity dilution and short-term profit-taking pressure following the recent surge driven by positive Phase 3 pneumococcal vaccine data.

The company's 31-valent pneumococcal vaccine candidate VAX-31 met all primary endpoints in the pivotal Phase 3 OPUS-1 trial, demonstrating immunogenicity superior to comparators Prevnar 20 and Capvaxive across age groups. The offering announcement, coming on the heels of a share price increase of over 50% on the trial results, prompted investor concerns about shareholder dilution, resulting in the intraday pullback.

Vaxcyte, Inc. is a clinical-stage biotechnology vaccine company developing novel protein vaccines to prevent bacterial infectious diseases. Its lead candidate VAX-31 is expected to support a Biologics License Application submission to the FDA in the first half of 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)